8 years of revenue, profit, cash flow and balance-sheet history through FY2025,
from SEC filings — with a computed, factual read of the trend.
Updated Overview →
Growth & profitability
Revenue has grown 88.2% per year over the past 5 years.
Operating margin has expanded, at 17.9% in the latest year.
Financial health
Total debt has grown slower than revenue (14.9% vs 88.2% per year).
Operating income covered interest expense 7.9× in the latest year.
Revenue & net income
RevenueNet income
Margins (gross / operating / net)
GrossOperatingNet
Return on equity & assets (ROE / ROA)
ROEROA
Free cash flow (CFO − capex)
Free cash flow
Cash vs total debt
CashTotal debt
Cash flow: operating / investing / financing
OperatingInvestingFinancing
Key annual figures
FY
Revenue
Net income
Gross M
Op M
ROE
ROA
FCF
Total debt
Cash
2025
$605M
$190M
59.9%
17.9%
40.2%
17.8%
$134M
—
$489M
2024
$442M
$36M
59.4%
8.5%
15.5%
4.4%
-$81M
—
$337M
2023
$242M
-$25M
63.8%
-11.9%
-18.2%
-3.5%
-$165M
—
$395M
2022
$93M
-$36M
69.8%
-33.6%
-19.3%
-13.1%
-$58M
$59M
$202M
2021
$30M
-$44M
69.9%
-130.3%
-65.1%
-32.8%
-$32M
$35M
$26M
2020
$26M
-$29M
64.9%
-102.9%
-27.7%
-18.9%
-$31M
$35M
$25M
2019
$24M
-$34M
58.7%
-125.4%
-61.4%
-31.9%
-$32M
$34M
$21M
2018
$13M
-$24M
44.1%
-155.5%
12.4%
-56.4%
-$26M
$34M
$21M
Revenue & net income
RevenueNet income
Margins (gross / operating / net)
GrossOperatingNet
Return on equity & assets (ROE / ROA)
ROEROA
Free cash flow (CFO − capex, quarterly)
Free cash flow
Cash vs total debt
CashTotal debt
Cash flow: operating / investing / financing
OperatingInvestingFinancing
Key quarterly figures
Quarter
Revenue
Net income
Gross M
Op M
ROE
ROA
FCF
Total debt
Cash
Mar '26
$174M
$7M
58.2%
7.6%
1.5%
0.5%
-$12M
—
$480M
Dec '25
$161M
$105M
58.1%
13.2%
22.3%
9.9%
$19M
—
$489M
Sep '25
$144M
$24M
58.8%
16.2%
6.8%
2.6%
$62M
—
$467M
Jun '25
$157M
$35M
61.4%
23.2%
11.0%
3.9%
$83M
—
$401M
Mar '25
$144M
$26M
61.5%
19.1%
9.6%
3.1%
-$30M
—
$311M
Dec '24
$122M
$7M
59.2%
7.1%
3.0%
0.9%
$6M
—
$337M
Sep '24
$109M
$4M
55.9%
3.6%
2.0%
0.5%
-$41M
—
$331M
Jun '24
$114M
$12M
60.6%
10.9%
6.4%
1.6%
$2M
—
$363M
Mar '24
$97M
$12M
61.9%
12.8%
7.6%
1.7%
-$48M
—
$351M
Dec '23
$81M
$4M
59.0%
3.2%
2.9%
0.6%
-$34M
—
$395M
Sep '23
$66M
-$25M
61.2%
-42.7%
-20.1%
-3.7%
-$115M
—
$428M
Jun '23
$52M
-$1M
70.0%
-1.7%
-0.7%
-0.1%
-$7M
—
$583M
Mar '23
$42M
-$3M
69.2%
-5.0%
-1.4%
-0.9%
-$10M
$59M
$196M
Dec '22
$31M
-$7M
66.0%
-21.6%
-3.6%
-2.4%
-$7M
$59M
$202M
Sep '22
$26M
-$7M
70.5%
-21.6%
-4.0%
-2.7%
-$17M
$59M
$205M
Jun '22
$21M
-$12M
69.9%
-47.5%
-22.6%
-9.8%
-$13M
$35M
$31M
Mar '22
$16M
-$11M
76.2%
-59.0%
-17.6%
-8.5%
-$20M
$35M
$18M
Dec '21
$10M
-$13M
72.3%
-117.2%
-18.6%
-9.4%
-$10M
$35M
$26M
Sep '21
$5M
-$13M
70.3%
-218.3%
-16.5%
-9.9%
-$9M
$35M
$23M
Jun '21
$8M
-$11M
68.4%
-120.8%
-12.0%
-7.6%
-$6M
$35M
$26M
Valuation over time
How the market has priced TMDX against its own fundamentals since 2023-03 —
each month-end's share price set against the most recent annual filing, so the multiple moves
as price runs ahead of (or behind) earnings. Split-adjusted.
The price-to-earnings ratio has fallen from 61.0× (Dec '24) to 12.1× (Nov '26).
The price-to-sales ratio has fallen from 28.1× (Mar '23) to 3.8× (Nov '26).
Price / earnings (P/E)
P/E
Price / sales (P/S)
P/S
Frequently asked questions
Is TMDX growing its revenue and profit?
Over the past 5 years, Transmedics Group, Inc.'s revenue has grown 88.2% per year. These are computed facts, not advice.
How much debt does TMDX have?
As of FY2025, Transmedics Group, Inc. reported — of total debt against $489M of cash; operating income covered interest expense 7.9×.
What is TMDX's profit margin?
In FY2025, gross margin was 59.9%, operating margin 17.9%, and net margin 31.4%.
What is TMDX's P/E ratio?
Transmedics Group, Inc.'s P/E (TTM) is 15.21 as of the 2026-11-02 close — market cap ÷ net income over the trailing twelve months where four consecutive quarters are reported, otherwise the latest fiscal year, the same figure as on the TMDX stock page. The valuation chart above sets each month-end's price against the latest annual net income instead, so its latest point (about 12.1× as of Nov '26) can differ. These are computed facts, not advice.
Where does this data come from?
All figures are extracted from the company’s SEC EDGAR/XBRL filings — 10-K annual reports and 10-Q quarterly reports (use the Annual / Quarterly toggle). Quarterly figures are derived from the as-filed statements (year-to-date amounts are differenced into discrete quarters). Growth rates and ratios are computed by tradmap; nothing here is investment advice.
Source: SEC EDGAR / XBRL (10-K + 10-Q filings) · prices EOD (Databento), split-adjusted; price return — dividends not reinvested ·
growth rates, valuation multiples & ratios computed by tradmap. Valuation uses each month-end price
against the latest annual filing. Informational only — not investment advice.